Abstract 519: Attenuation of mammary tumor growth by gap junction enhancer.

Abstract

Abstract Normal cells have functional gap junctional intercellular communication (GJIC), while cancer cells exhibit many defects in cellular communication that contribute to the loss of tissue homeostasis. It is believed that restoring GJIC is linked to drug sensitivity and reduction of tumorigenicity. Previous studies show that GJIC and neoplastic cellular growth are inversely related and small molecule targeting gap junction can alter tumor growth. A dose of 25 mg/kg gap junction enhancer (PQ) can cause a 77% decrease of xenograft T47D breast tumors. In addition these small molecules can induce a decrease of tumor growth by 110%, 129%, and 73% in the pre, early, and late stages of tumor development of the transgenic mouse strain, FVB/N-Tg(MMTV-PyVT)634Mul/J. Western blot analysis shows that the gap junction protein, Cx43, was highly expressed in the PQ-treated tumors compared to the controls. Data suggests that enhancement of GJIC attenuates tumor growth; specifically Cx43 plays a significant role in tumorigenesis. Establishment of a continuous line of mammary tumor cells from the malignant neoplasm of a female transgenic mouse demonstrates that PQs can cause an increase of Cx43 expression and subsequently trigger a decrease of cell viability. Overall, targeting gap junction by small molecule PQ has shed light to the dynamic of connexins and gap junctions in mammary tumors. Citation Format: Stephanie N. Shishido, Thu A. Nguyen. Attenuation of mammary tumor growth by gap junction enhancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 519. doi:10.1158/1538-7445.AM2013-519